Portfolio Company · Operating Co.

Delpharm

Pharmaceutical processing

backed byAndera Partners

ExitedPharmaceutical processing

Delpharm

a portfolio company of

Andera Partners

Status on record: Exited

Investment year: 2007

PE Firm Index

Who owns Delpharm?

Delpharm is listed as an exited portfolio company of Andera Partners on Andera Partners' own portfolio page. Andera Partners invested in Delpharm in 2007, per Andera Partners' portfolio page.

Company Snapshot

Delpharm is a Pharmaceutical processing company. Its owner on record, Andera Partners, is a private equity firm. Andera Partners lists 291 companies in the index, 36 of them in Pharmaceutical processing.

SectorPharmaceutical processing

Parent PE firmAndera Partners

Ownership statusExited

WebsiteNot on record

About the owner

Andera Partners

Strategy: Private Equity, Development Capital, Sponsorless Mezzanine Investment, Co-Invest, Infrastructure Investment
Sectors: Life Sciences, Biotechnologies, Mid-Caps
Companies in the index: 291

Andera Partners is a private equity asset management firm that invests in companies and their management to support growth and innovation.

Read the Andera Partners profile

Questions about Delpharm

Who owns Delpharm?

Delpharm is listed as an exited portfolio company of Andera Partners on Andera Partners' own portfolio page. Andera Partners invested in Delpharm in 2007, per Andera Partners' portfolio page.

What sector is Delpharm in?

Delpharm is in Pharmaceutical processing. Classified from the owner's portfolio label.

What else does Andera Partners own in Pharmaceutical processing?

Andera Partners lists 35 other Pharmaceutical processing companies in the index, including Adler Ortho, AgoMab, AM Pharma, Amolyt Pharma and Artios Pharma.

Sources

Andera Partners
https://www.anderapartners.com/en/investment-portfolio/

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Delpharm and does not provide investment advice.

Other portfolio companies of Andera Partners

6 of 290 shown

“Pôle Fine Art” Horus Finance

Transportation & Logistics

2CGroup

B2B/B2C services

A2IA

Software for document capture and recognition

Abivax

Therapeutic products

Abrisud

Development, production and distribution of swimming pool enclosures

ACB

Printed circuit board manufacturer

See the full Andera Partners portfolio.

Other Pharmaceutical processing companies held by Andera Partners

Adler Ortho

AgoMab AM Pharma Amolyt Pharma Artios Pharma Arvelle

Other Pharmaceutical processing portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Andera Partners

Status: Exited

Investment year: 2007

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.